ESPR Esperion Therapeutics Inc.

Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27

Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27

ANN ARBOR, Mich., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2023 financial results before the market opens on Tuesday, February 27, 2024.

Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click to pre-register to participate in the conference call and obtain your dial in number and PIN.

Already registered? Access with your PIN . 

A live audio webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.

Esperion Therapeutics

At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit and and follow us on Twitter at

Esperion Contact Information:

Investors:

Alexis Callahan



(406) 539-1762

  

Media:

Tiffany Aldrich



(616) 443-8438



EN
13/02/2024

Underlying

ESPREsperion Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Esperion Therapeutics Inc.

 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Conta...

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET® ANN ARBOR, Mich., May 14, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Patent and Trademark Office (USPTO) issued a U.S. Patent Term Extension (PTE) certificate for bempedoic acid, which is contained in NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets. The certificate extends the term of U.S. Patent No. 7,335,799 by five years through December 3, 2030. The PTE certificate was granted under the patent restoration prov...

May 14, 2024 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)...

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 8, 2024, the Company granted 16 new employees 62,300 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual...

May 10, 2024 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Reports First Quarter 2024 Financial Results

Esperion Reports First Quarter 2024 Financial Results – Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents Grew 43% Y/Y and 6% Q/Q, Increased Momentum from Label Expansions Expected Throughout 2024 – – Received U.S. FDA Approval of Broad New Label Expansions for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet, Becoming the First LDL-C Lowering Non-Statins to Prevent Heart Attacks and Reduce Cardiovascular Risk in Prima...

May 7, 2024 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion to Participate in Upcoming May Investor Conferences

Esperion to Participate in Upcoming May Investor Conferences ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations . JMP Securities’ Life Sciences Conference in New York on May 13, 2024, at 2:30 p.m. ET. Bank of America Securities’ 2024 Health Care Conference in Las Vegas on May 15, 2024, at 3:00 p.m. PT / 6:00 p.m. ET. H.C. Wainwright’s 2nd Annual BioConnect Investor Conference in New York on May ...

April 29, 2024 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion to Report First Quarter 2024 Financial Results on May 7

Esperion to Report First Quarter 2024 Financial Results on May 7 ANN ARBOR, Mich., April 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click to pre-register to participate in the conference call and obtain your dial in number and PIN. A live audio webcast can be accessed on the investor and media section of the Esperion webs...

April 23, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch